Other
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Restart Life Sciences Expands U.S. Footprint via Amazon Logistics Amidst Modest Revenue Growth and Capital Dilution

Executive Summary
- The most recent release (May 13, 2026) details the strategic entry of subsidiary Holy Crap Foods into the United States market using Amazon USA logistics.
- This expansion targets the health and wellness sector with a phased rollout starting on top-performing SKUs to mitigate cross-border shipping challenges.
- The company emphasizes regulatory compliance readiness and a data-driven approach to recapturing U.S. market share following consolidation in Canada.
- Previous news (May 8, 2026) announced a $100,000 private placement for purchase order financing to support manufacturing and fulfillment cash flow gaps typical of the CPG industry.
- Historical context shows the acquisition of Holy Crap Foods closed on February 27, 2026, adding over $1 million in annualized revenue and a manufacturing facility in Gibsons, BC.
- Revenue updates from April 2026 show total revenue exceeding $106,000 with significant YoY growth (46% wholesale, 32% Amazon channels).
Material Impact
- The U.S. market entry is a logical execution step following the February acquisition and April announcements regarding international expansion targets; it does not represent unexpected new information.
- The financing amount ($100,000) is immaterial relative to typical CPG expansion costs but sufficient for immediate working capital bridging, indicating limited liquidity rather than aggressive growth funding.
- Revenue figures remain small in absolute terms (~$106k/month), suggesting the company is still in a scaling phase with high sensitivity to operational execution risks.
- The stock price has remained stagnant ($0.09) despite positive news flow over the past month, indicating market skepticism regarding the scalability of these revenue gains or dilution concerns from warrants.
- No strategic investors (e.g., Sprott, Lundin) are mentioned in this release; previous financing relied on private placement and CEO warrant exercises, which increases shareholder dilution risk.
HEAL · Price
Company Overview
- Company: Restart Life Sciences Corp., a health and wellness focused entity transitioning from development to revenue generation via acquisition.
- Flagship Project: Holy Crap Foods Inc., acquired in February 2026, specializing in gut health/digestive wellness products (clean-label, high-fiber, non-GMO).
- Operations: Operates a lease-based manufacturing facility in Gibsons, BC, and maintains a Canadian retail distribution network of over 800 locations.
- Product Pipeline: Includes existing Holy Crap SKUs, new protein-based SKU under development with University of Manitoba collaboration, and cognitive health products (BrainQ, BrainBalls).
- Business Model: Hybrid model utilizing wholesale distribution, direct-to-consumer e-commerce, and third-party marketplaces (Amazon, Walmart.ca).
More from Restart Life Sciences Corp.
Jun 18, 2026 · 06:01